Cancer Death Rates in UK Plummet by Nearly a Third Since 1980s
Huge improvements in prevention, diagnosis, and treatment have driven a significant decline in cancer death rates across the United Kingdom, according to a recent report from Cancer Research UK. The rate of people dying from cancer has fallen by almost a third since the 1980s, marking a seismic shift in public health outcomes.
Key Statistics and Trends
Currently, about 247 in every 100,000 people die from cancer each year in the UK. This represents a 29% drop from the peak in 1989, when the rate was approximately 355 per 100,000. In the past decade alone, the death rate has decreased by 11%, showcasing ongoing progress.
Specific cancers have seen notable reductions. For instance, the death rate for ovarian cancer dropped by 19% between 2012-2014 and 2022-2024, while stomach cancer fell by 34% and lung cancer by 22%. Other declines include bowel cancer (6%), breast cancer (14%), cervical cancer (11%), leukaemia (9%), and oesophageal cancer (12%).
However, not all trends are positive. Some cancer death rates have increased in the last decade, including kidney cancer (up 5%), liver cancer (up 14%), eye cancer (up 26%), and gallbladder cancer (up 29%). Rates for thyroid, pancreatic, and melanoma cancers have remained stable.
Factors Behind the Decline
Dr. Sam Godfrey, the science engagement lead at Cancer Research UK, highlighted that these figures reflect decades of crucial scientific breakthroughs. "From vaccines that prevent cancer to kinder, more targeted treatments, thousands more people today can make memories, reach milestones, and spend precious time with their loved ones," he said.
Key drivers include smoking bans and the rollout of screening programmes for breast, bowel, and cervical cancers. The NHS cervical screening programme has contributed to a 75% fall in cervical cancer death rates since the 1970s. Additionally, the human papillomavirus (HPV) vaccine, introduced in 2008 and given to schoolchildren, has been instrumental in reducing cervical cancers, with about 6.5 million people vaccinated in the UK.
Better treatments have also played a role. For example, death rates for prostate cancer decreased by 11% in the past decade, partly due to drugs like abiraterone, developed by Cancer Research UK scientists, which blocks testosterone from fuelling prostate cancer.
Challenges and Future Outlook
Despite these gains, cancer remains Britain's biggest killer, causing about one in four deaths. Survival rates in the UK lag behind some European countries, such as Romania and Poland. A growing and ageing population means more people are being diagnosed with cancer—one person every 75 seconds in the UK—and the overall number of deaths continues to rise.
Recent reports have highlighted systemic issues. Last year, a Guardian analysis found that three-quarters of NHS hospital trusts are failing cancer patients, prompting experts to declare a national emergency. Additionally, Brexit has impacted the ability to offer life-saving new drugs via international clinical trials, with red tape and extra costs derailing progress.
In response, the government has pledged £2 billion to transform cancer services, aiming for faster diagnoses, quicker treatment, and better support by 2029. However, some cancer performance targets have not been met by the NHS since 2015, underscoring the need for continued investment and reform.
Dr. Godfrey emphasized that while the UK is a global leader in cancer research, future progress cannot be taken for granted. "It's essential that the government makes it easier and faster to set up clinical trials, as well as providing NHS staff with the time and space to carry out life-saving research," he stated.
